Compare PMT & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMT | PHAR |
|---|---|---|
| Founded | 2009 | 1988 |
| Country | United States | Netherlands |
| Employees | 7 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.2M | 885.7M |
| IPO Year | N/A | 2020 |
| Metric | PMT | PHAR |
|---|---|---|
| Price | $10.13 | $12.65 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $13.50 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 851.9K | 8.4K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 13.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.04 |
| Revenue Next Year | $1.55 | $2.51 |
| P/E Ratio | ★ $12.59 | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.83 | $9.54 |
| 52 Week High | $13.80 | $21.34 |
| Indicator | PMT | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 39.86 | 42.87 |
| Support Level | N/A | $11.88 |
| Resistance Level | $12.76 | $13.61 |
| Average True Range (ATR) | 0.23 | 0.49 |
| MACD | 0.04 | 0.12 |
| Stochastic Oscillator | 27.24 | 46.62 |
PennyMac Mortgage Investment Trust is a specialty finance company that invests mainly in residential mortgage loans and mortgage-related assets. The company's operations include activities such as the production and servicing of financial securities based on residential loans and the pooling and reselling of high-credit-quality mortgages. The company operates through three segments: correspondent production, credit-sensitive strategies, interest-rate-sensitive strategies. The Credit sensitive strategies segment generates income via investments in CRT arrangements, subordinate MBS, distressed loans, and real estate.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.